Humacyte’s Chief Medical Officer and Vascular Surgeon, Dr. Jeffrey Lawson, to Address Upcoming VEITHsymposium

Go Back

November 9, 2015

RESEARCH TRIANGLE PARK, N.C., — November 9, 2015 – Jeffrey H. Lawson, M.D., Ph.D., Chief Medical Officer of Humacyte, an innovator in biotechnology and vascular regenerative medicine, will present three sessions at the leading vascular specialist conference, the VEITHsymposium, November 17-23, 2015 in New York City at the New York Hilton-Midtown. Dr. Lawson, a distinguished vascular surgeon, will focus on new techniques in human tissue engineered arterial vascular access conduits, and how to optimize outcomes in hemodialysis access.

On Thursday, November 19 at 7:27 a.m., Dr. Lawson will present on “Human Tissue Engineered Vessels Are Finally Working as Lower Extremity Bypasses and Dialysis Access: Why and Prospects for the Future.” Additionally, Dr. Lawson will present on Saturday, November 21 on “Novel Therapies for Hemodialysis Vascular Access Dysfunction,” and “Expanding Role for Endoluminal Anastomosis in Vascular Access Surgery,” at 10:33 a.m., and 11:33 a.m., respectively.

Prior to his new role at Humacyte, Dr. Lawson helped to support the Company’s founder, Dr. Laura Niklason to develop an investigational human acellular vessel (HAV), HUMACYL™, to provide vascular access for patients with End Stage Renal Disease (ESRD) who require hemodialysis.

Humacyte received Fast Track designation for HUMACYL for vascular access in hemodialysis patients from the U.S. Food and Drug Administration in 2014 and has ongoing Phase II trials in the U.S. and EU for patients with ESRD who require vascular access for hemodialysis. Humacyte plans to initiate a global Phase III study for HUMACYL in the coming months.

“The VEITHsymposium has long been an outstanding meeting for education and innovation in the field of vascular science and surgery,” said Dr. Lawson. “As Humacyte approaches late-stage clinical trials of the company’s human acelluar vessel, we will review some of the key milestones from our preclinical and human phase II studies that have led to this exciting progress.”

Humacyte recently announced that it has raised $150 million committed Series B preferred stock financing. Funding will support the upcoming global Phase III clinical trials of HUMACYL and the development of future pipeline products with the potential to improve treatment outcomes for patients with a variety of vascular and non-vascular diseases, such as Coronary Artery Bypass, Replacement Trachea and Esophagus, and bypass for Peripheral Arterial Disease.

For more information on the VEITHsymposium, visit

About Humacyte
Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is

All statements, other than statements of historical fact, included in this announcement are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “will”, “anticipate”, “expect”, “believe”, “intend” and “should” or the negative of these terms or other comparable terminology. These statements relate to future events or Humacyte’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Humacyte’s actual results, performance or achievements to be materially different. Except as required by law, Humacyte assumes no obligation to update these forward-looking statements.

About VEITHsymposium
Now in its 42nd year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend VEITHsymposium, please visit or contact Pauline T. Mayer at 631.979.3780.